Characterization of a survival pathway controlled by FGFR4 in alveolar Rhabdomyosarcoma

被引：0
|
作者：
Wachtel, Marco
Schafer, Beat
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3418
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3418
引用
收藏
页数：3
相关论文
共 50 条
  • [11] First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
    Hagel, Margit
    Miduturu, Chandra
    Sheets, Michael
    Rubin, Nooreen
    Weng, Weifan
    Stransky, Nicolas
    Bifulco, Neil
    Kim, Joseph L.
    Hodous, Brian
    Brooijmans, Natasja
    Shutes, Adam
    Winter, Christopher
    Lengauer, Christoph
    Kohl, Nancy E.
    Guzi, Timothy
    CANCER DISCOVERY, 2015, 5 (04) : 424 - 437
  • [12] FIRST SELECTIVE SMALL MOLECULE INHIBITOR OF FGFR4 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMAS WITH AN ACTIVATED FGFR4 SIGNALING PATHWAY
    Hoeflich, K.
    Hagel, M.
    Miduturu, C.
    Sheets, M.
    Rubin, N.
    Weng, W.
    Stransky, N.
    Bifulco, N.
    Kim, J.
    Hodous, B.
    Brooijmans, N.
    Shutes, A.
    Winter, C.
    Lengauer, C.
    Kohl, N.
    Guzi, T.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S215 - S216
  • [13] Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
    Elisa Fiorito
    Patrycja Szybowska
    Ellen M. Haugsten
    Michal Kostas
    Geir F. Øy
    Antoni Wiedlocha
    Sachin Singh
    Sigve Nakken
    Gunhild M. Mælandsmo
    Jonathan A. Fletcher
    Leonardo A. Meza-Zepeda
    Jørgen Wesche
    British Journal of Cancer, 2022, 127 : 1939 - 1953
  • [14] Potent antitumor activity of a FGFR4 CAR-T in rhabdomyosarcoma.
    Cheuk, Adam Tai Chi
    Tian, Meijie
    Shivaprasad, Nityashree
    Highfill, Steven
    Milewski, David
    Brown, G. Tom
    Azorsa, Peter
    Schneider, Dina
    Gryder, Berkley
    Wei, Jun S.
    Song, Young Kwok
    Chou, Hsien-Chao
    Wu, Jerry
    Chung, Joon-Yong
    Belyea, Brian
    Linardic, Corinne
    Hewitt, Stephen M.
    Dropulic, Boro
    Orentas, Rimas
    Khan, Javed
    CANCER RESEARCH, 2022, 82 (12)
  • [15] Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
    Fiorito, Elisa
    Szybowska, Patrycja
    Haugsten, Ellen M.
    Kostas, Michal
    Oy, Geir F.
    Wiedlocha, Antoni
    Singh, Sachin
    Nakken, Sigve
    Maelandsmo, Gunhild M.
    Fletcher, Jonathan A.
    Meza-Zepeda, Leonardo A.
    Wesche, Jorgen
    BRITISH JOURNAL OF CANCER, 2022, 127 (11) : 1939 - 1953
  • [16] FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients
    S Streit
    D S Mestel
    M Schmidt
    A Ullrich
    C Berking
    British Journal of Cancer, 2006, 94 : 1879 - 1886
  • [17] FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients
    Streit, S.
    Mestel, D. S.
    Schmidt, M.
    Ullrich, A.
    Berking, C.
    BRITISH JOURNAL OF CANCER, 2006, 94 (12) : 1879 - 1886
  • [18] A role for FGFR4 in growth and survival of Ewing sarcoma cells
    Montoya, Justin J.
    Wai, Daniel H.
    Lee, David W.
    Azorsa, Peter A.
    Pepper, Oliver B.
    Arceci, Robert J.
    Azorsa, David O.
    CANCER RESEARCH, 2017, 77
  • [19] Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter
    Yu, SJ
    Zheng, L
    Asa, SL
    Ezzat, S
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2002, 283 (03): : E490 - E495
  • [20] A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4
    Tian, Meijie
    Jia, Katrina
    Wu, Jerry T.
    Wei, Jun S.
    Cheuk, Adam T.
    Zhang, Zhongmei
    Pope, Eleanor G.
    Shor, Boris
    Tumey, L. Nathan
    Khan, Javed
    CANCER RESEARCH, 2024, 84 (07)
12345